The Longevity Podcast: Optimizing HealthSpan & MindSpan
Welcome to a new era of conversation—where artificial intelligence explores what it means to live longer and better. Created and guided by Dr. Trinh, The Longevity Podcast uses AI hosts to bring scientific discovery, health innovation, and human wisdom together. Through AI-driven discussions inspired by real research and medical insight, each episode reveals practical tools for optimizing your healthspan and mindspan—rooted in science, shaped by compassion.
Mind. Body. Spirit.
Powered by Science, Guided by Humanity.
The Longevity Podcast: Optimizing HealthSpan & MindSpan
Why An Amyloid Positive Test Does Not Mean The Same Disease
Use Left/Right to seek, Home/End to jump to start or end. Hold shift to jump forward or backward.
A clean diagnosis feels like an X-ray: obvious problem, obvious fix. Alzheimer’s disease is the opposite, and the arrival of disease-modifying anti-amyloid therapies like lecanemab and donanemab makes that gap impossible to ignore. We dig into why real-world patients do not look like “pristine” clinical trial participants, and why a simple amyloid positive label can hide wildly different biology, risks, and likely outcomes.
We explore what happens when amyloid burden is patchy or borderline, how centiloid scores and CSF biomarkers (especially the amyloid beta 42 to 40 ratio) create a probabilistic gray zone, and why cognitive decline often reflects more than plaques alone. Cerebrovascular disease and white matter injury can team up with modest amyloid to push a brain over the edge, which changes what “treating the cause” even means.
Then we follow the fire inward to tau. Tau tangles disrupt neurons from the inside, and tau PET with Braak staging can reveal severe pathology even when someone still functions well, thanks to cognitive reserve. From there, we zoom out to the ATNIVS framework: Amyloid, Tau, Neurodegeneration, Inflammation, Vascular pathology, and Synuclein. We connect blood biomarkers like plasma NFL and GFAP to active neurodegeneration and neuroinflammation, and we explain why ARIA (amyloid-related imaging abnormalities) risk rises when fragile vessels, inflammation, and cerebral amyloid angiopathy collide with plaque-clearing antibodies.
Finally, we cover a provocative twist: seed amplification assays detecting hidden alpha-synuclein in a meaningful share of patients diagnosed with Alzheimer’s, pointing to copathology that can change prognosis and potentially mask drug benefit. If you care about Alzheimer’s biomarkers, precision neurology, and the future of combination therapies, listen through to the end, then subscribe, share the episode, and leave a review with your biggest takeaway.
This podcast is created by Ai for educational and entertainment purposes only and does not constitute professional medical or health advice. Please talk to your healthcare team for medical advice.
Never miss an episode—subscribe on your favorite podcast app!
Why Alzheimer’s Defies Binary Diagnosis
SPEAKER_01Usually um when you think about a medical diagnosis, there's this expectation of you know mechanical precision.
SPEAKER_00Aaron Powell Right, like a clear-cut answer.
SPEAKER_01Exactly. You break your arm, the x-ray shows that jagged white line, and the doctor just points to it. It's either broken or not broken. You put a caft on it, and you go home.
SPEAKER_00Yeah, it's a wonderfully binary system. The biology in that case is incredibly straightforward.
SPEAKER_01Aaron Powell But if we venture into the world of neurodegeneration, so specifically cognitive decline and Alzheimer's disease, that x-ray machine is well, it's utterly useless.
SPEAKER_00Right.
SPEAKER_01We are looking at a diagnostic landscape that is astonishingly murky.
SPEAKER_00Aaron Powell It really is. And things are getting even more complicated because of a massive shift happening in medicine right now.
SPEAKER_01Aaron Ross Powell Right, the new treatments.
SPEAKER_00Exactly. We are seeing a wave of new disease-modifying therapies. So drugs like Lacanimab and Doninamab, they're making their way out of clinical trials and into everyday medical practice. And I mean, the transition from a highly controlled trial to a real-world clinic is a profound shock to the system.
SPEAKER_01Aaron Powell, which is exactly what we're exploring for you today on this deep dive. We're looking at a pivotal editorial from the Journal of Prevention of Alzheimer's disease. This was published in May 2026 by Dr. Michael S. Rafi.
SPEAKER_00Yeah, it's a fantastic piece of writing.
SPEAKER_01It really is. He details how these new drugs are basically colliding with the messy, complicated reality of human biology.
SPEAKER_00Because in a clinical trial, you select pristine patients who fit very narrow specific criteria.
SPEAKER_01Right. They have to check all the boxes.
SPEAKER_00Exactly. But in the real world, patients do not fit into neat little boxes. The editorial argues that the traditional black and white way we diagnose Alzheimer's is completely
New Anti Amyloid Drugs Meet Reality
SPEAKER_00obsolete.
SPEAKER_01So we're moving past it.
SPEAKER_00We have to. We are moving toward a framework called ATNIVS, which looks at a patient's complete biological fingerprint.
SPEAKER_01Okay, let's unpack this because to appreciate this new framework, we really need to understand the old rules.
SPEAKER_00The binary rule.
SPEAKER_01Right. During the clinical trials for those new anti-amyloid drugs, eligibility was strictly binary. You either had amyloid plaques in your brain, meaning you were amyloid positive, or you didn't.
SPEAKER_00Just a simple yes or no.
SPEAKER_01Yeah, I like to think of it like a strict bouncer at a VIP club. You walk up, the bouncer checks your brain for amyloid, and you either have the risk can and get the treatment, or you're turned away.
SPEAKER_00And you know, regulatory agencies and insurance pairs strongly prefer that binary system because it is easy to manage.
SPEAKER_01It makes the paperwork simple.
SPEAKER_00Right. But the editorial highlights a fascinating real-world study by Kurihara and colleagues that dismantles that bouncer analogy completely.
SPEAKER_01Oh, really?
SPEAKER_00Yeah. They found that among patients treated in everyday practice, getting that amyloid wristband does not mean you have the same disease as everyone else in the club.
SPEAKER_01Wait, if they all have amyloid plaques, how are their diseases different?
SPEAKER_00Well, the study revealed massive biological variation. To start, 21% of the treated individuals only had regional amyloid positivity.
SPEAKER_01Regional. You mean like it's only isolated to certain neighborhoods of the brain rather than spread everywhere?
SPEAKER_00Exactly. In classic symptomatic Alzheimer's disease, the amyloid plaques typically form a diffuse blanket over the entire outer layer of the brain, the cortex.
SPEAKER_01Right. It's everywhere.
SPEAKER_00But in this 21% subgroup, the amyloid was patchy and localized. The researchers measured this using something called centeloid burden, which uh calculates the sheer density or weight of the plaques.
SPEAKER_01Okay.
SPEAKER_00And this group had a remarkably low centeloid score.
SPEAKER_01Aaron Powell So instead of a massive blizzard covering the whole landscape, they just have like a light dusting of snow and a few scattered areas.
SPEAKER_00That is a perfect visual. And clinically, this subgroup looked different too. They tended to be older and they were in much milder stages of cognitive decline.
SPEAKER_01Wait, hold on. If they only have a light dusting of localized amyloid, why are they in a clinic getting a heavy-duty drug like Lacanimab? I mean, why are they showing cognitive impairment at all?
SPEAKER_00Aaron Powell That puzzle goes to the heart of the editorial. It proves that while amyloid is a driver of the disease, it is not the sole cause of the patient's symptoms. Okay. If someone has a failing memory but only a tiny bit of amyloid, a copilot must be driving the damage. In this subgroup, the researchers found that copilot, it's cerebrovascular disease.
SPEAKER_01Aaron Powell Cerebrovascular disease. So um issues with the blood vessels inside the brain.
SPEAKER_00Aaron Powell Yes. They quantified this using physicus scores, which is a visual scale applied to MRI scans. It measures white matter lesions.
SPEAKER_01Aaron Ross Powell Which are what exactly?
SPEAKER_00Essentially, it shows areas where the microscopic blood vessels in the brain have thickened or become blocked over time. It is essentially the visible aftermath of thousands of microscopic mini strokes.
SPEAKER_01Oh wow. Thousands of them.
SPEAKER_00Yeah. The blood flow is restricted, so the brain tissue in those areas is slowly starved of oxygen.
SPEAKER_01Aaron Powell Oh, wow. So you have this one-two punch. The amyloid isn't enough to cause the symptoms on its own, but when you combine it with the poor blood flow and vascular damage, the brain's network starts to collapse.
SPEAKER_00Aaron Powell It's like a bridge.
SPEAKER_01If the bridge has a little bit of rust, the amyloid, it can still hold traffic. Yeah. But if it has rust and it gets hit by an earthquake, the vascular disease, the whole thing comes down.
SPEAKER_00Aaron Powell That analogy perfectly captures the mechanical synergy happening in the brain. The rust weakens the structure and the earthquake breaks it. And this highlights the danger of treating amyloid as a binary yes or no. If you give a patient a powerful drug to remove a tiny bit of rust, but the primary cause of their cognitive decline is ongoing earthquake damage, you're not actually
Patchy Amyloid And Vascular Damage
SPEAKER_00altering the course of their disease.
SPEAKER_01Aaron Powell So if a light dusting is enough to cause symptoms when there's vascular damage, uh, what happens when someone barely has any amyloid at all? How are we even drawing the line between amyloid positive and amyloid negative?
SPEAKER_00Aaron Powell Right, that's where it gets tricky. The researchers draw that line by analyzing the cerebrospinal fluid, or CSF, that's the liquid that bathes the brain and spinal cord. Specifically, they look at the ratio of two proteins, a beta 42 to a beta 40.
SPEAKER_01Why compare those two specific proteins? And what does a ratio actually tell us about the brain?
SPEAKER_00Aaron Powell Well, what's fascinating here is that it's an incredibly clever diagnostic tool based on how these proteins behave. Your brain constantly produces both of them. A beta 40 is relatively short and floats around harmlessly. It is soluble.
SPEAKER_01Okay, so it just washes away.
SPEAKER_00Exactly. But a beta 42 is slightly longer, and crucially, it is extremely sticky.
SPEAKER_01Aaron Powell So the 42 is the one that clumps together to form the plaques.
SPEAKER_00Yes. When a beta 42 starts clumping together to form solid plaques in the brain, it gets trapped there. It stops flowing down into the spinal fluid. Oh I see. So if a doctor does a lumbar puncture and sees a severe drop in a beta 42 compared to the harmless a beta 40, they know the sticky protein is currently accumulating inside the patient's brain.
SPEAKER_01Aaron Powell That is brilliant. Yep. You aren't just looking for the presence of the bad protein, you're looking for its absence in the fluid because it's stuck upstream.
SPEAKER_00Exactly.
SPEAKER_01But I imagine that drop in the ratio doesn't happen overnight.
SPEAKER_00No, it happens very gradually. And the study found that even though all the treated patients were technically stamped as amyloid positive to qualify for the drug, a subset of them hovered right on the edge of the cutoff.
SPEAKER_01Oh really?
SPEAKER_00Yeah. They fell into a murky, likely positive range.
SPEAKER_01Aaron Powell So they basically barely crossed the finish line.
SPEAKER_00Aaron Powell Which reveals a fundamental truth here. Biomarker thresholds are probabilistic, not absolute. Biology is a dial, it's not a light switch.
SPEAKER_01That makes sense.
SPEAKER_00The medical system wants a clear cutoff to determine who gets a prescription. But a patient hovering near that cut point is in a transitional biological state.
SPEAKER_01Aaron Powell Meaning they might just be at the very, very beginning of their amyloid accumulation.
SPEAKER_00Aaron Powell Or they might have mixed etiologies, meaning they have a negligible amount of amyloid, and their memory loss is actually being caused by something else entirely. Wow. The editorial stress is that this raises a massive unknown. We are treating a biological gray area with a black and white therapeutic protocol, and we honestly do not know how effective or how safe these anti-amyloid therapies will be for borderline patients.
SPEAKER_01Here's where it gets really interesting for me.
CSF Ratios And The Gray Zone
SPEAKER_01If the amyloid line is so blurry, and amyloid itself isn't necessarily the direct immediate killer of the brain cells, what is? Like if amyloid is the match that starts the fire, what is the actual fire?
SPEAKER_00Aaron Ross Powell The Fire is a protein called Tau. Amyloid plaques build up slowly outside the brain cells, setting a toxic stage. But tau proteins operate inside the neurons.
SPEAKER_01Inside the cell. So how does tau actually destroy the cell?
SPEAKER_00Well, inside every neuron, there's a transport system that looks like tiny train tracks carrying nutrients from the center of the cell down to the synapses.
SPEAKER_01Okay, I'm picturing it.
SPEAKER_00In a healthy brain, tau acts like the wooden railroad ties, holding the tracks straight and stable. But in Alzheimer's, the tau proteins become deformed. They detach from the tracks and tangle together into clumps.
SPEAKER_01So the railroad ties just rot away.
SPEAKER_00The ties dissolve, the tracks collapse, and the neuron literally starves to death from the inside out.
SPEAKER_01That sounds brutal.
SPEAKER_00It is. This tau pathology remains the absolute strongest biological correlate of clinical impairment. Where the tau goes, brain cell death follows.
SPEAKER_01Aaron Powell And to measure this, the study used a highly advanced PE tracer called uh 18F MK6240, and they found a wild variance in the tau burden among these real-world patients getting licanomap.
SPEAKER_00The variance was staggering. They measured the spread of the fire using break stages.
SPEAKER_01Aaron Powell Break stages.
SPEAKER_00Yeah. Break stage zero means virtually no tau tangles, while stage six means the tangles have spread out of the memory centers and swept across the entire brain, causing massive widespread destruction.
SPEAKER_01Aaron Powell What totally blew my mind in the editorial was the disconnect between those stages and the patient's actual symptoms.
SPEAKER_00Right. The clinical presentation.
SPEAKER_01Yeah. You had patients who performed identically on memory tests in the clinic. I mean, they were at the exact same clinical stage of cognitive decline, but their brains looked completely different on the PET scans.
SPEAKER_00Aaron Powell It's incredible. You can have someone with minimal Tao burden who shows undeniable severe cognitive impairment. Yeah. On the flip side, you have patients with highly advanced tau pathology, break stage five or six, who are still functioning quite well, categorized only with mild cognitive impairment.
SPEAKER_01That's wild.
SPEAKER_00They have a raging fire in their brain, yet they are still holding a conversation and paying their bills.
SPEAKER_01How is that even possible? If the tau is actively starving the cells to death, how can someone with a massive fire be doing fine while someone with a tiny spark is losing their memory?
SPEAKER_00It comes down to a concept called cognitive reserve. It's basically the brain's mechanical resilience. Okay. Some brains develop incredibly dense, redundant neural networks over a lifetime. If a tau tangle destroys one pathway, a highly resilient brain will just route the electrical signal around the damage, like a GPS finding a detour when a highway is blocked.
SPEAKER_01So the person with high tau just have more detours built into their brain.
SPEAKER_00Exactly. They can sustain massive structural damage before the clinical symptoms appear simply because their brain keeps improvising workarounds.
SPEAKER_01That's amazing.
SPEAKER_00And the person with low tau but severe symptoms likely lacks those redundant pathways, or they have other copathologies like the vascular earthquake damage we talked about that have already destroyed their detours.
SPEAKER_01Aaron Powell So how does knowing a patient's tau level change the decision to prescribe an amyloid drug if you're just clearing out the amyloid plaques? Why does the internal tau fire matter?
SPEAKER_00It matters heavily for setting realistic expectations for the patient's future. How so? If a patient comes in with extremely high tau levels, break stage five or six, the cellular fire is already raging out of control. Removing the amyloid matches at that late stage might not slow down the clinical decline in a meaningful way.
SPEAKER_01Ah, I see.
SPEAKER_00The runaway train has already left the station.
SPEAKER_01The structural damage is already done.
SPEAKER_00Exactly. But if patient has a very low tau, they might be the ideal candidate. You remove the amyloid matches before the widespread internal fire ever really ignites, potentially offering genuine long-term disease modification.
SPEAKER_01Aaron Powell That reframes the entire conversation. You aren't just telling a patient, you know, take this drug and you'll get better. You're assessing their specific cellular fire to see if a specific hose
Tau Burden And Cognitive Reserve
SPEAKER_01will actually put it out.
SPEAKER_00Aaron Powell Which brings us to the broader ATNIVS framework, the editorial champions. We've covered the A for amyloid and the T for tau. Right. But the framework demands we look at the hidden amplifiers of the disease. Neurodegeneration, which is the N inflammation, the I, vascular pathology, the V, and alpha synucline, the S.
SPEAKER_01Okay, let's look at those hidden amplifiers. How are we measuring the N, the neurodegeneration?
SPEAKER_00The study utilized plasma markers, basically advanced blood tests. For neurodegeneration, they measured plasma NFL or neurofilament light chain.
SPEAKER_01What are neurofilaments?
SPEAKER_00They're the structural scaffolding proteins that give a neuron its physical shape. When a brain cell finally dies and bursts open, that scaffolding shatters and spills out into the surrounding fluid, eventually making its way into the bloodstream. So measuring high levels of NFL in the blood gives you a real-time metric of active, ongoing brain cell death. It's like seeing structural debris floating in the water after a shipwreck.
SPEAKER_01That is a dark image, but it makes perfect sense. And what about the eye for inflammation?
SPEAKER_00For inflammation, they measured GFE, a protein released by astrocytes. Astrocytes are essentially the maintenance and immune crew of the brain.
SPEAKER_01The cleanup crew.
SPEAKER_00Yeah. When they detect damage like amyloid plaques or dying cells, they activate and try to clear the debris. But in neurodegenerative disease, they often become hyperactive, leading to chronic, toxic brain inflammation. High GFA means the brain's immune system is stuck in overdrive.
SPEAKER_01And we already covered the V, the vascular pathology causing those microscopic blood vessel blockages. So why are these three, the dying cells, the chronic inflammation, and the vascular damage, so critical when a doctor is considering an anti-amyloid therapy?
SPEAKER_00The most urgent reason is safety, specifically the risk of a severe side effect called ARIA.
SPEAKER_01ARI, amyloid-related imaging abnormalities. This is the major safety warning on drugs like lacanimab, involving brain swelling and microhemorrhages.
SPEAKER_00Right. To understand why ARIA happens, you have to look at how the drug works mechanically. These drugs are monoclonal antibodies designed to forcefully strip amyloid out of the brain. Okay. But amyloid doesn't just sit in isolated plaques, it also embeds itself deeply into the walls of the brain's blood vessels, a condition called cerebral amyloid angiopathy.
SPEAKER_01So the drug is literally attacking the amyloid inside the blood vessel walls.
SPEAKER_00Yes. It triggers the brain's immune cells to attack and clear that embedded amyloid. If you do this in a patient whose blood vessels are already fragile and thickened from vascular disease and surrounded by hyperactive angry astrocytes causing inflammation, the cleanup process is incredibly destructive.
SPEAKER_01That sounds dangerous.
SPEAKER_00It is. As the amyloid is stripped away, the compromised vessel walls become porous, they leak fluid, causing brain swelling, or they rupture entirely, causing bleeding.
SPEAKER_01So if a doctor only looks at the binary amyloid wristband and ignores the inflammation and vascular damage, they might prescribe a drug to a patient whose blood vessels literally cannot survive the structural stress of the cleanup.
SPEAKER_00Exactly. It's a profound safety risk that is completely invisible if you only focus on the amyloid.
ATNIVS Profiling And ARIA Risk
SPEAKER_01That is terrifying. But there's one more letter in this framework that caught me completely off guard.
SPEAKER_00The S.
SPEAKER_01The S at the very end. Alpha Sinucline.
SPEAKER_00That finding is arguably the most provocative paradigm shift in the entire editorial.
SPEAKER_01Because alpha synucline is a totally different protein. It's a one that misfolds and clumps together to form Lewy bodies, which are the hallmark of Parkinson's disease and Lewy body dementia. It has completely different mechanisms than amyloid or tau.
SPEAKER_00It does. It attacks different regions of the brain and causes a very different cascade of cellular failure.
SPEAKER_01Yet the study ran tests on these real-world patients, people diagnosed with Alzheimer's disease who are receiving an Alzheimer's drug, and found that roughly 25% of them tested positive for alpha-sinuclein in their spinal fluid. A quarter of the patients.
SPEAKER_00And many of them showed minimal, if any, clinical signs of Lewy body disease. Clinically, they just look like they had Alzheimer's.
SPEAKER_01How do the researchers even find it if there were no symptoms?
SPEAKER_00They used a revolutionary new tool called a seed amplification assay, or SAA.
SPEAKER_01How does an SAA actually work? Like how do you find a microscopic trace of a different disease hidden in the spinal fluid?
SPEAKER_00It's an ingenious piece of molecular engineering. Alpha synucleane causes damage by misfolding and then corrupting the healthy proteins around it, forcing them to misfold too.
SPEAKER_01Like a domino effect.
SPEAKER_00Right. The SAA exploits this behavior. Researchers take a tiny sample of the patient's spinal fluid and place it in a tube filled with perfectly healthy synthetic alpha cytocline.
SPEAKER_01So they mix the patient's fluid with normal proteins.
SPEAKER_00Then they shake it. If the patient has even a microscopic trace of the misfolded seed in their fluid, it will start corrupting the healthy synthetic proteins in the tube, triggering a rapid chain reaction.
SPEAKER_01It's like dropping a single zombie into a crowded room to see if an outbreak starts.
SPEAKER_00That is exactly the mechanism. Within hours, the misfolded proteins multiply until the machine can easily detect them. Wow. And using this tool, we discovered that 25% of these Alzheimer's patients are actively harboring a second, completely distinct neurodegenerative disease.
SPEAKER_01So a quarter of these people have two separate brain-destroying fires burning at the same time.
SPEAKER_00If we connect this to the bigger picture, we call it coproteinopathy. The biology does not care about our neat diagnostic boxes.
SPEAKER_01Obviously not.
SPEAKER_00And having senuclein copathology drastically alters a patient's prognosis. The two diseases interact, accelerating the overall cognitive decline. And crucially, we currently have very little data on how a brain dealing with hidden alpha snuclein responds to an anti-amyloid therapy.
SPEAKER_01Because if you have a whole second army of proteins
Hidden Lewy Pathology And The Future
SPEAKER_01destroying your neurons, just putting away the amyloid matches might not even slow the decline down.
SPEAKER_00Right. The clinical benefit might be entirely masked by the progression of the hidden Lewy body pathology.
SPEAKER_01So what does this all mean? Zooming out from all the specific proteins and mechanisms, the core takeaway for you listening is this Alzheimer's disease is not a single monolith.
SPEAKER_00No, it's an umbrella term for a highly individualized biological event.
SPEAKER_01Anti-amyloid therapies are remarkable breakthroughs, but they do not operate in a vacuum. The effects of removing amyloid unfold against an incredibly complex backdrop of internal tau fires, dying structural scaffolding, vascular rust, brain inflammation, and completely hidden co-conspirators like alpha-sinucline.
SPEAKER_00The ATNIVS profile provides the multidimensional map required for true precision medicine. It allows a physician to look at two patients who both have early Alzheimer's and understand why they have entirely different trajectories, entirely different side effect risks, and require completely different care plans.
SPEAKER_01We started this conversation talking about the comforting simplicity of an x-ray, a clean binary problem with a clean binary fix. But the human brain is more like a massive, intricate orchestra.
SPEAKER_00A very fragile orchestra.
SPEAKER_01And if 25% of these patients have hidden alpha synucline and others have heavy vascular damage or raging towel fires, it means the string section is out of tune, the brass is playing the wrong song, and the percussion is completely missing. Clearing out the amyloid is like fixing a single broken violin string. It's a start. But you can't fix one string and expect the symphony to sound perfect. It leaves you wondering if you're putting out one fire in a burning house, what does the future of combination therapies really look like?
SPEAKER_00That's the only way forward.
SPEAKER_01Imagine a bespoke personalized cocktail of therapies tailored to target your exact biological signature. We have to trade the comfort of the simple X ray for the power of a multi dimensional map. And while those diagnostic waters might look murky right now, mapping out every single instrument in that orchestra is exactly what will help us finally navigate them.